

nancy in type 2 diabetic women. Maternal weight gain and the rate of caesarean deliveries were lower in type 2 diabetes. Gestational age at birth was significantly higher and the rate of large infants for gestational age lower in infants of women with type 2 diabetes. The rates of perinatal mortality and major congenital malformations were comparable in both groups. First-trimester A1C in type 2 and type 1 diabetic mothers with perinatal mortality was 9.9 and $8.1 \pm 1.2\%$, respectively. Among pregnancies complicated by major congenital malformations, first-trimester A1C was $>7\%$ in 84% of women with type 1 diabetes and only in one woman (16.7%) with type 2 diabetes ($P = 0.006$). Neonatal distress respiratory syndrome was more frequent in infants of mothers with type 1 diabetes.

In our study, pregnancy outcomes in type 2 diabetic women were, if anything, similar to those with type 1 diabetes. In fact, women with type 2 diabetes had lower rates of large infants for gestational age, neonatal respiratory distress syndrome, and caesarean delivery.

As in some of the studies available, we found no significant differences in perinatal mortality or major congenital malformations between women with type 2 and type 1 diabetes (1–2). However, the results of five recent publications (3–7) suggest that type 2 diabetes could even represent a higher risk of perinatal mortality or congenital malformations than that conferred by type 1 diabetes. Similar rates of preconceptional care in women with type 1 and type 2 diabetes in our study could explain this discrepancy, as could the fact that gestational age at first visit to the clinic was comparable in both type 1 and type 2 diabetic women who did not undergo preconceptional care.

In our study, congenital malformations in type 2 diabetes were not related to poor first-trimester metabolic control in most cases. The concurrence in women with type 2 diabetes of factors other than glycemic control, such as obesity and older age, may account for this finding (8).

In conclusion, our study shows that pregnancy outcomes in type 2 diabetes are better than in type 1 diabetes when type 2 diabetic women receive as much intensified medical treatment during preconception and pregnancy as that given to type 1 diabetic women.

NATALIA HILLMAN, MD
LUCRECIA HERRANZ, MD, PHD

PILAR M. VAQUERO, MD
AFRICA VILLARROEL, MD
ALBERTO FERNANDEZ, BM
LUIS F. PALLARDO, MD, PHD

From the Division of Diabetes, Department of Endocrinology and Nutrition, University Hospital La Paz, Madrid, Spain.

Address correspondence to Natalia Hillman Gadea, Division of Diabetes, Department of Endocrinology and Nutrition, University Hospital La Paz, 28046 Madrid, Spain. E-mail: nhillman.hulp@salud.madrid.org.

DOI: 10.2337/dc06-0680

© 2006 by the American Diabetes Association.



References

1. Feig DS, Palda VA: Type 2 diabetes in pregnancy: a growing concern. *Lancet* 359:1690–1692, 2002
2. Diabetes and Pregnancy Group, France: French multicentric survey of outcome of pregnancy in women with pregestational diabetes. *Diabetes Care* 26:2990–2993, 2003
3. Omori Y, Minei S, Testuo T, Nemoto K, Shimizu M, Sanaka M: Current status of pregnancy in diabetic women: a comparison of pregnancy in IDDM and NIDDM mothers. *Diabetes Res Clin Pract* 24 (Suppl.):S273–S278, 1994
4. Brydon P, Smith T, Proffitt M, Gee H, Holder R, Dunne F: Pregnancy outcome in women with type 2 diabetes mellitus needs to be addressed. *Int J Clin Pract* 54: 418–419, 2000
5. Cundy T, Gamble G, Townend K, Henley PG, MacPherson P, Roberts AB: Perinatal mortality in type 2 diabetes mellitus. *Diabet Med* 17:33–39, 2000
6. Clausen TD, Mathiesen E, Ekblom P, Hellmuth E, Mandrup-Poulsen T, Damm P: Poor pregnancy outcome in women with type 2 diabetes. *Diabetes Care* 28:323–328, 2005
7. Roland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC: The pregnancies of women with type 2 diabetes: poor outcomes but opportunities for improvement. *Diabet Med* 22:1774–1777, 2005
8. Garcia-Patterson A, Erdozain L, Ginovart G, Adelantado JM, Cubero JM, Gallo G, de Leiva A, Corcoy R: In human gestational diabetes mellitus congenital malformations are related to pre-pregnancy body mass index and to severity of diabetes. *Diabetologia* 47:509–514, 2004

COMMENTS AND RESPONSES

Glucose Abnormalities in Patients With Hepatitis C Virus Infection: Epidemiology and Pathogenesis

Response to Lecube et al.

We read with great interest the review article by Lecube et al. (1) on the pathogenic factors specifically linking hepatitis C virus (HCV) infection and glucose abnormalities. After analyzing the different mechanisms by which HCV is thought to contribute to the development of type 2 diabetes, Lecube et al. focus their attention on the role of proinflammatory cytokines, in particular tumor necrosis factor (TNF)- α and interleukin-6. They suggest that the activation of the TNF- α system in HCV-infected patients, which has been directly related to insulin resistance in their recent study (2), could be related to the T-helper (Th)1 immune response observed in the course of HCV infection. Accordingly, as shown in Fig. 1 of their review article, the activation of the TNF- α system following the Th1 immune-mediated response is central to the pathogenesis of both liver fibrosis and insulin resistance associated with HCV infection.

However, an apparent paradox is raised by an attempt to fit such interpretation with well-acquired data and the most recent evidence from literature. Indeed, a vigorous Th1 cytokine response has been classically observed in patients who clear their HCV infection, either spontaneously (3) or in response to antiviral treatment (4,5). By contrast, recent studies have demonstrated that insulin resistance is independently associated with a poor response to antiviral therapy in HCV patients (6,7), consistent with previous observations on the lower success rate of interferon alone or interferon plus ribavirin in obese and diabetic patients. Therefore, it is difficult to understand how an increased Th1 immune response, which is protective in relation to viral clearance, can be, at the same time, the major determinant of insulin resistance and responsible for a poor response to antiviral treatment.

